Walgreens Boots Alliance Nixes Dispersing Abortion Medication In 20 Republican States
Walgreens Boots Alliance Inc (NASDAQ: WBA) reportedly confirmed that it would not dispense abortion pills in several states where they remain legal.
Biden Admin’s Upcoming Cybersecurity Strategy Can Potentially Put Businesses, Software Provides On Collision Course
The Biden administration is poised to release a new national cybersecurity strategy that aims to make software companies liable for security hacks rather than the companies facing the hack.
UBS Expects Retail Inflow Of Around $87B Driving Next Leg Of Chinese Stock Rally: Report
According to UBS Group AG (NYSE: UBS), China's stock market may see an inflow of around 600 billion yuan ($86.8 billion) of excess savings from the nation's households.
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
As previously announced, Valneva SE (NASDAQ:VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new…
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s
The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…
AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says
Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…
JNJ’s Consumer Health Business Separation Will Remove Uncertainty Cloud From Company: Why This Analyst Wants Visibility
Guggenheim initiated the coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and a $161 price target. The analyst agrees with the…
Analyst Sits On Fence While Initiating Calliditas Citing ‘Near-Term Opportunity But Longer-Term Questions’
Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ:CALT) with a Neutral rating and an $18 price target. The analyst is impressed with…
Guggenheim Creates Bullish Pitch For ANI Pharma On Progress With Cortrophin Launch
Guggenheim launched its coverage on ANI Pharmaceuticals Inc (NASDAQ:ANIP) with a price target of $55 and a Buy recommendation citing a “bullish view”…
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
Guggenheim starts coverage on Chinook Therapeutics Inc (NASDAQ:KDNY) with a Buy rating and a $43 price target, being ‘bullish’ on the immunoglobulin…